GlaxoSmithKline Plc is taking multiple steps to use its vaccine capacity to deliver new products to treat and prevent Covid-19. At the same time, the economic disruption caused by the pandemic is a risk factor for the company’s overall business, Emma Walmsley, the chief executive, told journalists on 29 July.
